FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 354:2616-2617 June 15, 2006 Number 24 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Nissen, S. E. PubMed Citation

To the Editor: Nissen et al. (March 23 issue)¹ report on the ACAT Intravascular Atherosclerosis Treatment Evaluation (ACTIVATE) study, in which patients with coronary disease were treated with an enzyme acyl–coenzyme A:cholesterol acyltransferase (ACAT) inhibitor, pactimibe, to evaluate the potential for beneficial effects on coronary-artery atherosclerosis. We believe the authors' sweeping conclusion that ACAT inhibition is not an effective strategy for limiting atherosclerosis and that such treatment may promote atherogenesis is premature.

As the article pointed out, there are two types of ACATs (ACAT1 and ACAT2), which have distinct physiologic roles. Studies in animals show that the inhibition of ACAT1 . . . [Full Text of this Article]

This article has been cited by other articles:

• Chang, T.-Y., Li, B.-L., Chang, C. C. Y., Urano, Y. (2009). Acyl-coenzyme A:cholesterol acyltransferases. Am. J. Physiol. Endocrinol. Metab. 297: E1-E9 [Abstract] [Full Text]